Excessive sympathetic activity has a crucial role in the initiation and progression of chronic structural alterations in the heart and vessels associated with hypertension. Angiotensin II type 1a receptors (AT 1a R) in paraventricular nucleus (PVN) are involved in sympathetic overdrive and hypertension. The present study was designed to investigate the cardiovascular beneficial effects of the AT 1a R gene silence in the PVN in hypertension. The PVN microinjection of recombinant adenoviral vectors expressing either artificial microRNA (amiRNA) targeting AT 1a receptors (Ad-miR-AT 1a ) or control microRNA (Ad-miR-Con) were carried out in spontaneously hypertensive rats (SHR) and normotensive Wistar rats. The vectors were labels with green fluorescent protein (GFP). The successful amiRNA interference was confirmed by the AT 1 receptors reduction and the GFP expression in the PVN. Significant depressor effects were observed from day 5 to day 20 after Ad-miR-AT 1a treatment in SHR. Ad-miR-AT 1a treatment decreased the ratio of left ventricular weight to body weight, cross-sectional areas of myocytes, myocardial fibrosis, media thickness, and the media/lumen ratio of the aorta and the mesenteric artery in SHR. The amiRNA interference reduced the basal sympathetic activity, cardiac sympathetic afferent reflex, plasma norepinephrine and plasma angiotensin II in SHR. These results indicate that amiRNA interference targeting AT 1a R in the PVN decreases arterial blood pressure, blunts sympathetic activity and improves myocardial and vascular remodeling in SHR.
INTRODUCTION
As a worldwide challenge, hypertension is a powerful independent risk factor for the development of cerebrovascular disease, myocardial infarction, heart failure and peripheral artery disease. Sympathetic overdrive has a key role in the progression of hypertension and related pathological changes.
1,2 Sympathectomy surgery in spontaneously hypertensive rats (SHR) attenuates cardiac fibrosis and hypertension. 3 Central sympathetic deactivation has been considered as an important strategy for arresting hypertension and regressing-related cardiac structural alterations. 4, 5 Paraventricular nucleus (PVN) is critical in the integration of sympathetic outflow and cardiovascular activity via its projections to rostral ventrolateral medulla and intermediolateral column of spinal cord. 6 Inhibiting the PVN dramatically reduces sympathetic vasomotor tone, 7 whereas activating the PVN increases sympathetic outflow in SHR. 8 Bilateral electrolytic lesions of the PVN attenuate the sympathetic activity and the development of hypertension in SHR. 9, 10 These results indicate the importance of the PVN in the development and progression of hypertension in SHR.
It has been found that the angiotensin II type 1 receptors (AT 1 R) in the PVN are increased in SHR 11 and renovascular hypertensive rats. 12 Our recent studies have shown that angiotensin II (Ang II) in the PVN increases sympathetic activity and arterial pressure, and antagonist of AT 1 R in the PVN attenuates the enhanced sympathetic activity in renovascular hypertensive rats. 12 Functional studies using selective gene knockout models have shown that the AT 1a receptors (AT 1a R) were responsible for blood pressure control while AT 1b receptors (AT 1b R) for drinking activity. 13 Microinjection of adenoviruses encoding AT 1a R small hairpin RNA into the PVN inhibits acute increases in arterial blood pressure but had no significant effects on the basal arterial pressure in normal rats. 14 However, it remains unknown whether gene silence of the AT 1a R in the PVN has beneficial effects on hypertension. The present study was designed to determine whether silencing of the AT 1a R in the PVN by artificial microRNA (amiRNA) interference attenuates the hypertension and sympathetic activity, and improves the cardiovascular remodeling in SHR.
RESULTS

Green fluorescence protein fluorescence and expression in brain
The green fluorescence protein (GFP) fluorescence and expression appeared as early as 24 h, peaked at 2 weeks and lasted at least 4 weeks after viral injection. Immunofluorescence analyses showed that GFP-positive cells were localized in the PVN including the parvicellular and magnocellular divisions of the PVN. No obvious GFP-positive cell was found in the adjacent brain regions or other areas throughout the brain in most of the rats (Figure 1 ). Only in four rats, a noticeable fluorescence can been found on the wall of the third ventricle besides the PVN and very-weak fluorescence on the wall of central canal, the wall of lateral ventricles and the commissural part of the nucleus of the solitary tract.
AT 1 R expression in PVN The recombinant adenoviral vectors encoding either the amiRNA targeting AT 1a R (Ad-miR-AT 1a ) significantly decreased the expression of AT 1 R in the PVN between the 5th and the 20th day after the viral injection in SHR (Figure 2a) . The maximal changes of expression of AT 1 R were found at the 10th day after viral injection. Therefore, we chose the end of the second week after viral injection to compare the changes of the AT 1 R protein expression among the four groups. After recombinant adenoviral vectors encoding control amiRNA (Ad-miR-Con) treatment, the AT 1 R expression in the PVN in SHR was much higher than that in Wistar rats. After Ad-miR-AT 1a treatment, the AT 1 R expression in the PVN was significantly decreased in both SHR and Wistar rats (Figure 2b ).
Systolic blood pressure of tail artery in conscious state
The Ad-miR-AT 1a caused a significant decrease in systolic blood pressure (SBP) of tail artery in conscious SHR from the 5th to the 20th day after viral injection but not in Wistar rats (Figure 2c ). The Ad-miR-AT 1a treatment had no significant effect on the heart rate (HR) in either SHR or Wistar rats (Figure 2d ). The maximal depressor effect was found at the 10th day (À43 ± 3 mm Hg) in SHR, which was consistent with the time-course of the AT 1 R expression change in the PVN (Figure 2a) . Therefore, acute experiments were carried out at the end of the second week after viral injection for determining the changes of all the indices listed below in four groups.
Mean arterial pressure in femoral artery and HR in anesthetized state To confirm the depressor effects of Ad-miR-AT 1a , the mean arterial pressure (MAP) and HR were recorded in anesthetized state.
The MAP and HR were significantly higher in SHR than that in Wistar rats. Ad-miR-AT 1a treatment caused a significant decrease in the MAP but not in the HR in SHR. Ad-miR-Con had no significant effect on both MAP and HR in Wistar rats (Table 1) .
Hypertensive left ventricular hypertrophy and remodeling The left ventricular weight and the ratio of left ventricular weight to body weight were increased in SHR, which were attenuated by the Ad-miR-AT 1a treatment ( Table 1) . The cross-sectional area of cardiomyocytes was significantly increased in SHR, which was blunted by the Ad-miR-AT 1a treatment (Figure 3 ). Both myocardial interstitial and perivascular fibrosis were significantly increased in SHR. Ad-miR-AT 1a treatment significantly attenuated the perivascular fibrosis but not myocardial interstitial fibrosis in spite of a mild inhibitory trend (Figure 4 ).
Hypertensive vascular remodeling Compared with Wistar rats, the lumen diameter (L) in SHR was decreased in the mesenteric artery but not in the renal artery and the aorta, while media thickness (M) and the M/L in SHR were increased in the three arteries. Ad-miR-AT 1a attenuated the M and M/L of the aorta and the mesenteric artery but not the M and M/L of the renal artery in SHR ( Figure 5 ). These results suggested that the hypertensive remodeling of the aorta and the mesenteric arteries could be ameliorated by the AT 1 R gene silence in the PVN.
Sympathetic nerve activity
Considering that the enhanced sympathetic activity contributes to hypertension and cardiovascular remodeling 4, 5 and that Ang II in the PVN increases sympathetic outflow and blood pressure, 12 the sympathetic nerve activity was investigated in three ways. First, plasma norepinephrine (NE) level, an indirect index of sympathetic activity, 15 was increased in SHR, which was normalized by Ad-miR-AT 1a treatment (Figure 6a ). Second, depressor response to ganglionic blockade with hexamethonium in conscious rats was used as another index to indicate the peripheral sympathetic activity. 16 Compared with Wistar rats, the SHR exhibited a greater depressor response to hexamethonium, which was attenuated by Ad-miR-AT 1a treatment (Figure 6b) . Third, the cardiac sympathetic afferent reflex (CSAR), which partially contributes to the sympathetic activation, 17 was enhanced in SHR, which was normalized by the Ad-miR-AT 1a treatment (Figure 6c ). Plasma Ang II Plasma Ang II was increased in SHR and Ad-miR-AT1a treatment reduced the plasma Ang II in SHR (Table 1) .
DISCUSSION
This study provides evidence that the reduction of AT 1a R expression in the PVN causes a profound and prolonged protection against hypertension in SHR. Besides reducing blood pressure, the PVN-targeted amiRNA interference ameliorates pathological left ventricular hypertrophy and hypertensive cardiovascular remodeling. The results suggest the importance of AT 1a R in the PVN in neural cardiovascular control, and support the view that AT 1a R in the PVN mainly participates in the pathophysiological process of hypertension. The study also provides information that amiRNA targeting AT 1 R in the PVN in hypertension effectively blunt the sympathetic activity that contributes to the elevated blood pressure and the development of hypertension-related pathological changes.
The decrease in blood pressure in SHR caused by amiRNA interference was consistent to the time-course of AT 1a gene silence and GFP expression. However, no depressor effect was observed in normotensive Wistar rats although there was a 60% decrease in AT 1 R expression. The results were supported by our recent findings that AT 1 R antagonist in the PVN decreases the MAP and renal sympathetic nerve activity in the acute experiment of renovascular hypertensive rats but not in normal rats. 12 It was reported that adenoviruses encoding AT 1a small hairpin (shRNA) in the PVN in normal rats blunted the acute Ang II-induced elevation in MAP, but had no significant effect on basal MAP. 14 We speculate that the enhanced AT 1a R activity in the PVN has an important pathogenical role in triggering and sustaining the hypertension.
The left ventricular hypertrophy associated with hypertension is recognized as a strong, virtually independent cardiovascular risk factor. 18 A very inspiring result in our study is the noticeably improved cardiovascular remodeling with Ad-miR-AT 1a treatment in SHR, as most notably evidenced by attenuated left ventricular hypertrophy, myocardial and perivascular fibrosis, and vascular remodeling. It is interesting that the treatment blunts the perivascular fibrosis rather than the myocardial interstitial fibrosis, which is consistent with that the infusion of Ang II results in the Po0.05 vs the same species of rats subjected to Ad-miR-Con treatment (n ¼ 6 for each group). (c) The SBP and HR in conscious state before and after microinjection of Ad-miR-Con or Ad-miR-AT 1a in SHR and Wistar rats. *Po0.05 vs SHR treated with Ad-miR-Con (n ¼ 8 for each group). fibrosis mainly in perivascular area but not in myocardial interstitial space. 19 The arterial media hypertrophy in SHR is observed in Branches III and IV of mesenteric arteries. 20 The remodeling of the large and small arteries contributes to the development and end-organ damages of hypertension. 21 In the present study, the M and M/L were increased in the aorta and the Branches III of the mesenteric arteries in SHR. The inward eutrophic remodeling in the aorta and the resistance vessels was improved after amiRNA interference targeting AT 1a R in the PVN of SHR, which may be beneficial to attenuate the organ damage and cardiovascular complications of hypertension. In addition, the amiRNA interference had no effect on improving the remodeling of the main renal artery, which is supported by the findings that anti-hypertension treatment in SHR did not prevent renal vessel wall thickening but reversed the hypertrophy of other arterial vessel walls. 22 On the other hand, we found that the blood pressure returned to the higher level but the modeling partially reverted 6 weeks after viral injection.
An important finding in this study was that the AT 1a R gene silence in the PVN decreased the plasma NE, and inhibited the sympathetic activity and the CSAR accompanied with improved hypertension and cardiovascular remodeling in SHR. It is probable that the AT 1a R gene silence in the PVN resulted in an inhibition in sympathetic activity and a decrease in blood pressure, which in turn improved the myocardial and vascular remodeling. A deficiency in the present study is that the complex relationship among the over-enhanced sympathetic activity, antihypertensive effects and cardiovascular remodeling is difficult to be well clarified. Nevertheless, it has been well established that the sympathetic overdrive is a causative factor of hypertension and there is a close relationship between sympathetic activity and cardiaovascular structural alterations.
1,2 When the hypertensive state is complicated by the presence of organ damage, the magnitude of the sympathetic overdrive appears to be potentiated. 5 The cardiac structural alterations are directly related to sympathetic activity. 23 These evidence indicate the importance of intervention of the excessive sympathetic activity in antihypertension. It has been shown that intracerebroventricular injection of Ad-AT 1a -shRNA had no significant effect on plasma Ang II in normal mice. 24 Intravenous injection of antisense Po0.05 vs the same species of rats subjected to Ad-miR-Con treatment (n ¼ 8 for each group).
oligodeoxynucleotides against angiotensinogen reduced the increased plasma Ang II level in SHR. 25 In the present study, the plasma Ang II was increased in SHR. The amiRNA interference targeting AT 1a R in the PVN normalized the plasma Ang II in SHR, which may be beneficial to the attenuation of hypertension and cardiovascular remodeling.
Besides the PVN, the AT 1 R in some other brain regions such as rostral ventrolateral medulla, subfornical organ, nucleus tractus solitarius (NTS) and anterior hypothalamic area are involved in the regulation of sympathetic outflow and blood pressure. Microinjection of AT 1 R antagonist, losartan or valsartan, into the RLVM, 26 subfornical organ, 27 NTS 28 or anterior hypothalamic area 29 attenuated the effects of Ang II in the corresponding regions on blood pressure and sympathetic outflow in normal or SHR rats. However, no obvious anti-hypertensive effect of the AT 1 R antagonist in these regions has been reported. It is important to note that microinjection of losartan into the PVN decreased the sympathetic outflow and blood pressure in acute experiments of renovascular hypertensive rats. 12 The present study found that interference of AT 1a R in the PVN attenuated hypertension, inhibited sympathetic activity and improved the myocardial and vascular remodeling in SHR lasting at least 3 weeks. The results indicate the importance of AT 1 R in the PVN in the pathogenesis of hypertension.
Adenoviruses allow highly efficient delivery of relatively large transgenes to the brain, and infect both neuronal and glial cell types. 30, 31 The viruses used in the present study are considered specific for just the AT 1a R and not for AT 1b R or AT 2 R for the following reasons. First, high level of AT 1a R mRNA but only verylow AT 1b R mRNA expression was found in the PVN of rat. 32 Second, a single gene encodes the AT 1 R in humans, whereas two AT 1 R genes in rodents, located on different chromosomes, each known to encode AT 1a R and AT 1b R. The rodent AT 1a R is thought to most resemble human AT 1 R, because it exhibits a similar function, cellular and tissue distribution, whereas AT 1b R exhibits a much more restricted expression profile. 33 Furthermore, the pressor effects of central Ang II could be ascribed selectively to AT 1a R, whereas the central dipsogenic actions of Ang II related the presence of AT 1b R. 13 Third, the RNA interference selectively silences AT 1a R but had no significant effect on AT 1b R or AT 2 R. 24, 34 Fourth, the pressor response caused by the PVN microinjection of Ang II or by electrical stimulation of subfornical organ was attenuated by AT 1 R antagonist but unaffected by the AT 2 R antagonist. 35 Last, four different sequences targeting AT 1a R genes were designed using the BLOCK-iTTM RNAi Designer (Invitrogen, Carlsbad, CA, USA). The target gene sequences were verified using a BLAST search. Designed using a unique set of parameters, including an advanced mismatch alignment search, these artificial miRNAs should be effective and specific at knocking down the target gene.
The amiRNA interference technology displays some advantages over conventional siRNA and shRNA interference approaches. 36 Importantly, amiRNA can be designed to target any gene of interest, 37 and amiRNA-based hairpin is easier to achieve tissuespecific RNA interference because the flexibility of Pol II promoter used in this study allows tissue-specific expression and can mitigate shRNA-associated toxicity in the brain. 38 The designed amiRNA can regulate the expression of protein-coding genes efficiently and negatively through translational inhibition and RNA decay. These characteristics make amiRNA a powerful biological tool for therapeutic applications. 39 In summary, our study provides evidence that microRNA interference targeting AT 1a R in the PVN decreases arterial blood pressure, blunts sympathetic activity, and improves myocardial and vascular remodeling in SHR. The AT 1a R in the PVN has vital roles in the pathogenesis of hypertension, sympathetic activation and cardiovascular remodeling. These findings suggest that the AT 1a R in the PVN can be taken as an important target against hypertension and some related structural abnormality.
MATERIALS AND METHODS Animals
Procedures involving rats were approved by the Experimental Animal Care and Use Committee of Nanjing Medical University and conformed to the Guide for the Care and Use of Laboratory Animal published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Thirteen-week-old male SHR and Wistar rats were purchased from Vital River Laboratory Animal Technology Co. Ltd (Beijing, China) and housed on a 12-h light/dark cycle in a temperature-controlled room with standard chow and tap water ad libitum. Acute experiments were carried out under anesthesia induced by intraperitoneal injection of urethane (800 mg kg À1 ) and a-chloralose (40 mg kg
À1
). Supplemental doses of urethane and a-chloralose were administered to maintain an adequate depth of anesthesia during experiments.
Construction and validation the viral amiRNA-mediated knockdown
Four different sequences targeting AT 1a R genes were designed using the BLOCK-iT RNAi Designer (http://rnaidesigner.invitrogen.com/rnaiexpress/) and verified using a BLAST search. The sequence showed an 80% reduction effect in mRNA expression determined with real-time reverse-transcription PCR was chosen (Invitrogen). The AT 1a R microRNA-based hairpin sequence (shRNA-mir hairpin structure) was 5-ATCCGAAGGCCGGTAAGAAAG GTTTTGGCCACTGACTGACCTTTCTTAGGCCTTCGGAT-3. The above micro-RNA-based hairpin sequence, targeting nucleotides ranging from 721 to 741 of the rat AT 1a -coding sequence (GenBank accession no. NM-030985), consists of antisense target sequence (first 21 nucleotides in bold) and the sense target sequence (nucleotides 1--8 and 11--21 in italics) as well as a constant 19 nucleotides middle sequence from the miR-155 hairpin loop. The designed amiRNA sequences pairing to the AT 1a R mRNA was shown in Figure 7 . The pcDNA6.2-GW/EmGFP-miR-neg control plasmid was used as the control vector. The amiRNA and control sequences were cloned into recombinant adenoviral vectors. Ad-miR-AT 1a or Ad-miR-Con (1 Â 10 12 plaque-forming units per ml) were constructed and validated by Invitrogen Corporation and stored at À80 1C until they were used. All of the viral vectors contained the GFP as a reporter to track adenovirus-mediated expression. Po0.05 vs the same species of rats subjected to Ad-miR-Con treatment.
Viral microinjection
The rat was anesthetized with sodium pentobarbital (50 mg kg
À1
, intraperitoneal) and placed in a stereotaxic frame (51600, Stoelting, Chicago, IL, USA). The viruses were bilaterally microinjected into the PVN (50 nl for each side). The stereotaxic coordinates of PVN were 1.8 mm caudal from bregma, 0.4 mm lateral to the midline and 7.9 mm ventral to the dorsal surface, which was in accordance with Paxinos & Watson's rat atlas.
Western blot analysis for AT 1 R and GFP expression Sample tissues were collected and homogenized as previously reported. 40 Proteins were separated on a 10% SDS--PAGE and transferred to a nitrocellulose membrane (Pall, Pensacola, FL, USA). Membranes were probed with primary antibody to AT 1 R (1:300, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or GFP (1:300, Santa Cruz Biotechnology). Goat antirabbit IgG (1:5000) was used as secondary antibody. After incubated with enhanced chemiluminescence (Pierce, Rockford, IL, USA) and visualized by exposing to BioMax films (Kodak, Rochester, NY, USA), the membranes were stripped and probed with a mouse monoclonal anti-b-actin primary antibody (1:300, Santa Cruz Biotechnology) and rabbit anti-mouse secondary antibody. The results were expressed as the ratio of the optical density of the interested band divided by that for b-actin band.
Measurement of SBP
The SBP of tail artery was measured in conscious state using a noninvasive computerized tail-cuff system (NIBP, ADInstruments, Sydney, Australia) as previously reported. 12 The SBP was measured consecutively for more than a month with an interval of 5 days from 13:00 to 15:00. The measurements were considered valid only when the difference of five consecutive readings was o5 mm Hg. The mean of the five readings was calculated as the SBP of the rat.
Assessment of hypertensive left ventricular hypertrophy
After the heart, left ventricle including interventricular septum and right ventricle were weighed, the left ventricle tissue was fixed and sectioned (5 mm). In hematoxylin and eosin-stained sections, myocyte cross-sectional area was determined in the left ventricular lateral-mid free wall including epicardial and endocardial portions. 41 In Masson's trichrome-stained sections, total interstitial fibrosis and perivascular fibrosis in myocardium were quantitatively analyzed by morphomzetry. The total interstitial fibrosis was evaluated as the sum of the total collagen area excluding perivascular areas divided by the sum of to connective tissue area plus the myocardial area in the visual field. The perivascular fibrosis was evaluated in the intramuscular arteries and arterioles, and calculated as the area of fibrosis surrounding the artery divided by the area occupied by the artery. 42 
Assessment of hypertensive vascular remodeling
The descending thoracic aorta, main renal artery and the third-order branches of the mesenteric artery were isolated (2--3 mm long), embedded in paraffin, cut into 5-mm thick cross-sections, and stained with Masson's trichrome staining. The structural changes of these arteries were observed using a light microscope. The M, L and the M/L were used as indexes of vascular remodeling. 43 
Measurement of plasma NE
The blood sample was collected from carotid artery to a tube containing ethylene diamine tetraacetic acid-K. It was centrifuged and mixed in an antioxidizing stabilizer sodium metabisulphite (5.2 mM). Plasma NE level was detected by high-performance liquid chromatography with YWG-C18 column (250 mm Â 4.6 mm, 5 mm) and electrochemical detection (Waters 2465, Milford, MA, USA) as previously reported. 40 Pharmacological analysis of peripheral sympathetic tone
The response of MAP to ganglionic blockade was used to evaluate basal sympathetic nerve activity as previously reported in conscious rats. 44 A depressor effect was induced by intravenous administration of hexamethonium hydrochloride (30 mg kg À1 ). The maximal decrease in the MAP was considered as an index of sympathetic activity.
Evaluation of CSAR
The CSAR was evaluated by the efferent renal sympathetic nerve activity response to the epicardial application of a piece of filter paper (3 Â 3 mm) containing capsaicin (1.0 nmol in 2.0 ml of saline). 17 
Observation of GFP fluorescence
To determine the GFP expression and identify the microinjection sites, the brains of the rats were removed and sectioned into 5 mm at the end of experiments. The fluorescence was observed under a fluorescence microscope (BX51, Olympus, Tokyo, Japan).
Measurement of plasma Ang II
Plasma Ang II was measured with commercial ELISA kits (R&D systems, Minneapolis, MN, USA) according to the manufacturer's descriptions. Briefly, after 96-well plates were incubated with an antibody specific for rat Ang II, samples and standard diluent buffer were added, incubated and washed. Horseradish peroxidase-conjugated solution was added and then washed out. The reactions were stopped with stop solution and the final solution read at 450 nm using an ELISA plate reader. Protocols Protocol 1. To evaluate the time window and range of the gene expression in the brain, the GFP fluorescence distribution and GFP expression in the PVN and other brain regions before, 24 h, 1 week, 2 weeks, 3 weeks and 4 weeks after the viral injection in SHR.
Protocol 2. To determine the time window and efficacy of the gene silence, the AT 1 R protein expression in the PVN was determined every 5 days for more than a month in SHR before and after microinjection of Ad-miR-AT 1a .
Protocol 3. To determine the time window of the depressor effects, the SBP of tail artery and HR were determined every 5 days for a month before and after viral microinjection in the four groups of conscious rats. We found that the maximal effects of the gene silence on AT 1 R expression and SBP were observed at the 10th day after the viral injection. Therefore, the following experiments were carried out 2 weeks after the viral microinjection.
Protocol 4. The blood sample was collected for measuring plasma NE and Ang II 2 weeks after viral microinjection in the four groups of rats. The brain was removed for determining the AT 1 R expression, and the heart, aorta, renal artery and the mesenteric artery were harvested for histological analysis.
Protocol 5. The MAP response to ganglionic blockade was determined 2 weeks after viral microinjection in the four groups of rats.
Protocol 6. The CSAR was evaluated 2 weeks after viral microinjection in the four groups of rats. To minimize the confounding effect of baroreceptor and vagal afferents on sympathetic drive, bilateral vagotomy and arterial baroreceptor denervation were carried out before determining the CSAR as our previously reported. 12 
Statistical analysis
All data are expressed as mean±s.e. and were analyzed using SPSS 16.0. (SPSS Inc, Chicago, IL, USA). Statistical significance was evaluated by two-way or one-way ANOVA as appropriate, followed by Bonferroni's post-hoc test for multiple comparisons. Po0.05 was considered statistically significant.
